Menu Search
Equities

Cardiff Oncology Inc

XE7C:DUS

Cardiff Oncology Inc

Actions
  • Price (EUR)2.77
  • Today's Change-1.07 / -27.90%
  • Shares traded250.00
  • 1 Year change+176.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cardiff Oncology Inc had net income fall 7.07% from a loss of 38.70m to a larger loss of 41.44m despite a 26.42% increase in revenues from 386.00k to 488.00k.
Gross margin--
Net profit margin-6,143.91%
Operating margin-6,711.28%
Return on assets-49.98%
Return on equity-58.84%
Return on investment-57.60%
More ▼

Cash flow in USDView more

In 2023, Cardiff Oncology Inc increased its cash reserves by 32.47%, or 5.31m. Cash Flow from Investing totalled 36.20m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 30.89m for operations while cash from financing was breakeven.
Cash flow per share-0.905
Price/Cash flow per share--
Book value per share1.15
Tangible book value per share1.15
More ▼

Balance sheet in USDView more

Cardiff Oncology Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 21.66m.
Current ratio4.97
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.